Why the study?
Does rosuvastatin reduce the primary outcome in older patients with systolic heart failure?
Does rosuvastatin reduce the primary outcome in older patients with systolic heart failure?
Rosuvastatin does not reduce the primary outcome or all-cause mortality in older patients with systolic heart failure, but it reduces cardiovascular hospitalizations.
Rosuvastatin was not associated with reduced primary outcomes or mortality in older systolic HF; hypothesis-generating for CV hospitalization reduction.
Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
No takes yet. Share an insight, caveat, or question.
Kjekshus et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: